Total amount: € 0,00
HOW TO ORDER
A Journal on Endocrine System Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118
Minerva Endocrinologica 2000 March;25(1):1-3
Plasmatic endothelin-1 levels in hyperthyroid patients before and after antithyroid therapy
Cesareo R. 1, Tarabuso A. 1, Di Benedetto M. 1, Lacerna F. 2, Reda G. 2
1 Division of Internal Medicine, Ciriè Hospital, Ciriè (Turin);
2 Division of Internal Medicine, S. Pertini Hospital, Rome
Background. The Endothelin-1 (ET-1) is a powerful vasoconstrictor peptide produced by endothelial cells in many vascular diseases probably as a response to vessel damage. In hyperthyroidism as in other endocrinological diseases elevated ET-1 plasma levels have been found.
Methods. The effect of antithyroid therapy on ET-1 plasmatic levels was evaluated by measuring ET-1 plasma levels before and 2 and 6 months after treatment with methimazole in 14 patients affected by hyperthyroidism.
Results. The hyperthyroid patients had significantly higher ET-1 levels than the controls (18.85±5.7 vs 10.9±2.1 pg/ml), while after treatment no difference was found. The ET-1 plasma levels of hyperthyroid patients correlated closely with the raised thyroid metabolic activity independently of its cause. It is possible that the increased ET-1 levels in hyperthyroid patients are the expression of blood vessel damage caused by high thyroid hormone levels.
Conclusions. Moreover the results of this study could suggest that, in future, ET-1 plasmatic levels might be considered as a functional thyroid index in hyperthyroid diseases.